Affordable Access

deepdyve-link
Publisher Website

Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate?

Authors
  • Cushing, Melissa M1
  • Haas, Thorsten2
  • Karkouti, Keyvan3, 4
  • Callum, Jeannie5, 6, 7
  • 1 Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • 2 Department of Anesthesia, Zurich University Children's Hospital, Zurich, Switzerland. , (Switzerland)
  • 3 Peter Munk Cardiac Centre, University Health Network, Toronto, Canada. , (Canada)
  • 4 Department of Anesthesia and Pain Management, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada. , (Canada)
  • 5 Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada. , (Canada)
  • 6 Laboratory Medicine Program, University Health Network, Toronto, Canada. , (Canada)
  • 7 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. , (Canada)
Type
Published Article
Journal
Transfusion
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jun 01, 2020
Volume
60 Suppl 3
Identifiers
DOI: 10.1111/trf.15614
PMID: 32478877
Source
Medline
Language
English
License
Unknown

Abstract

The importance of the targeted treatment of acquired hypofibrinogenemia during hemorrhage with a concentrated fibrinogen product (either cryoprecipitate or fibrinogen concentrate) cannot be underestimated. Fibrinogen concentrate is a pathogen inactivated, pooled product that offers a highly purified single factor concentrate. Cryoprecipitate is a pooled product that comes with a spectrum of other coagulation factors which may further enhance (additional procoagulant effect) or even disturb (prothrombotic risk) hemostasis. The pros and cons of each product are discussed. © 2019 AABB.

Report this publication

Statistics

Seen <100 times